Recent studies on retatrutide, a dual agonist for glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, indicate encouraging outcomes in treating weight gain and type 2 diabetes. Preliminary information from clinical assessments show substantial reductions in body weight and i